| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Hebei Changshan Biochemical Pharmaceutical Co. Ltd (SHE: 300255)
300255 Technical Analysis
5
| As on 22nd Nov 2024 300255 STOCK Price closed @ 18.95 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 9.64 & Strong Buy for SHORT-TERM with Stoploss of 5.04 we also expect STOCK to react on Following IMPORTANT LEVELS. |
300255STOCK Price
| Open | 20.71 | Change | Price | % |
| High | 20.95 | 1 Day | -2.15 | -10.19 |
| Low | 18.95 | 1 Week | -3.00 | -13.67 |
| Close | 18.95 | 1 Month | 6.77 | 55.58 |
| Volume | 41223963 | 1 Year | 13.67 | 258.90 |
| 52 Week High 24.09 | 52 Week Low 4.44 | ||||
SHE China Most Active Stocks
| 000564 | 2.96 | -1.00% |
| 002131 | 2.71 | 9.72% |
| 300459 | 6.22 | -4.45% |
| 300059 | 25.90 | -5.44% |
| 300058 | 10.37 | -3.45% |
| 000100 | 4.59 | -4.57% |
| 000725 | 4.24 | -2.97% |
| 002354 | 5.50 | 2.61% |
| 000981 | 1.71 | -4.47% |
| 002583 | 22.50 | -10.00% |
SHE China Top Gainers Stocks
SHE China Top Losers Stocks
| 300255 Daily Charts |
300255 Intraday Charts |
Whats New @ Bazaartrend |
300255 Free Analysis |
|
|
300255 Important Levels Intraday
| RESISTANCE | 22.80 |
| RESISTANCE | 21.57 |
| RESISTANCE | 20.80 |
| RESISTANCE | 20.04 |
| SUPPORT | 17.86 |
| SUPPORT | 17.10 |
| SUPPORT | 16.33 |
| SUPPORT | 15.10 |
300255 Forecast November 2024
| 4th UP Forecast | 19.68 |
| 3rd UP Forecast | 19.45 |
| 2nd UP Forecast | 19.3 |
| 1st UP Forecast | 19.16 |
| 1st DOWN Forecast | 18.74 |
| 2nd DOWN Forecast | 18.6 |
| 3rd DOWN Forecast | 18.45 |
| 4th DOWN Forecast | 18.22 |
300255 Weekly Forecast
| 4th UP Forecast | 19.87 |
| 3rd UP Forecast | 19.58 |
| 2nd UP Forecast | 19.39 |
| 1st UP Forecast | 19.21 |
| 1st DOWN Forecast | 18.69 |
| 2nd DOWN Forecast | 18.51 |
| 3rd DOWN Forecast | 18.32 |
| 4th DOWN Forecast | 18.03 |
300255 Forecast2024
| 4th UP Forecast | 60.53 |
| 3rd UP Forecast | 47.2 |
| 2nd UP Forecast | 38.95 |
| 1st UP Forecast | 30.71 |
| 1st DOWN Forecast | 7.19 |
| 2nd DOWN Forecast | -1.05 |
| 3rd DOWN Forecast | -9.3 |
| 4th DOWN Forecast | -22.63 |
Hebei Changshan Biochemical Pharmaceutical Co. Ltd ( SHE China Symbol : 300255 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
300255 Business Profile
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of heparin and related products in China. Its API products include heparin sodium injections, heparin calcium and lithium injections, heparinoid, LMW heparins, and sodium hyaluronate. The company also provides dalteparin and enoxaparin sodium injections, and nadroparin calcium injections, as well as sildenafil citrate tablets. It markets and sells its products to approximately 30 countries worldwide. Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was founded in 2000 and is based in Shijiazhuang, China. Address: No. 9, Fuqiang Road, Shijiazhuang, China
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service